New drug aims to help transplanted hearts last longer
NCT ID NCT03644667
Summary
This study tested whether adding the drug tocilizumab to standard anti-rejection medicines leads to better results one year after a heart transplant. Researchers enrolled 385 recent heart transplant recipients to see if the drug reduces organ rejection, harmful antibody development, and improves heart function. Participants were randomly assigned to receive either tocilizumab or a placebo, in addition to their regular care, and were followed for up to two years.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART TRANSPLANT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Allegheny General Hospital (PAAG)
Pittsburgh, Pennsylvania, 15212, United States
-
Baylor University Medical Center (TXTX)
Dallas, Texas, 75246, United States
-
Cedars Sinai Medical Center (CACS)
Beverly Hills, California, 90211, United States
-
Cleveland Clinic Foundation (OHCC)
Cleveland, Ohio, 44195, United States
-
Columbia University Medical Center (NYCP)
New York, New York, 10032, United States
-
Duke University Medical Center (NCDU)
Durham, North Carolina, 27710, United States
-
Hospital of the University of Pennsylvania (PAUP)
Philadelphia, Pennsylvania, 19104, United States
-
Massachusetts General Hospital (MAMG)
Boston, Massachusetts, 02114, United States
-
Montefiore Medical Center (NYMA)
The Bronx, New York, 10467, United States
-
Mount Sinai Medical Center (NYMS)
New York, New York, 10029, United States
-
Northwestern Memorial Hospital (INLM)
Chicago, Illinois, 60611, United States
-
Penn State Health: Milton S. Hershey Medical Center (PAHE)
Hershey, Pennsylvania, 17033, United States
-
St. Luke's Hospital of Kansas City (MOLH)
Kansas City, Missouri, 64111, United States
-
Stanford Health Care (CASU)
Stanford, California, 94305, United States
-
Tampa General Hospital (FLTG)
Tampa, Florida, 33606, United States
-
Tufts Medical Center (MANM)
Boston, Massachusetts, 02111, United States
-
University of California, San Diego: Sulpizio Cardiovascular Center (CASD)
La Jolla, California, 92037, United States
-
University of Nebraska Medical Center (NEUN)
Omaha, Nebraska, 68198, United States
-
University of Utah (UTMC)
Salt Lake City, Utah, 84132, United States
-
Vanderbilt University Medical Center (TNVU)
Nashville, Tennessee, 37232, United States
Conditions
Explore the condition pages connected to this study.